4//SEC Filing
NAVIDEA BIOPHARMACEUTICALS, INC. 4
Accession 0001225208-14-008077
CIK 0000810509operating
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 5:21 PM ET
Size
10.5 KB
Accession
0001225208-14-008077
Insider Transaction Report
Form 4
LARSON BRENT L
VP Finance and CFO
Transactions
- Exercise/Conversion
Common Stock
2014-03-10$0.49/sh+50,000$24,500→ 372,996 total - Sale
Common Stock
2014-03-10$1.96/sh−41,500$81,340→ 319,184 total - Tax Payment
Common Stock
2014-03-10$1.99/sh−12,312$24,501→ 360,684 total - Exercise/Conversion
Stock Option (Right to Buy)
2014-03-10−50,000→ 0 totalExercise: $0.49Exp: 2014-07-28→ Common Stock (50,000 underlying)
Holdings
- 93,217(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Sales were effected to generate funds required to cover tax obligations arising from expiring options or the vesting of shares of restricted stock. The transaction is matchable under Section 16(b) of the Securities Exchange Act with Mr. Larson's purchase of 5,000 shares of common stock at $1.39 per share on November 8, 2013. As a result, Mr. Larson will pay the company $2,850, representing the full amount of the profit realized in connection with the short-swing transaction.
- [F2]Option vests 1/3 of the underlying shares annually beginning on the first anniversary of the date of grant.
Documents
Issuer
NAVIDEA BIOPHARMACEUTICALS, INC.
CIK 0000810509
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000810509
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 5:21 PM ET
- Size
- 10.5 KB